First in Human Study of IMGN151 in Recurrent Gynaecological Cancers
← catalyst calendarNCT05527184 · readout ≤ 193 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
256actual
Sites
58
Countries
Australia, Belgium, Canada +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-01-11 | actual | When the study began enrolling |
| Primary completion | Feb 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Feb 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2022-09-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Endometrial Cancer
- High Grade Serous Adenocarcinoma of Ovary
- Primary Peritoneal Carcinoma
- Fallopian Tube Cancer
- Cervical Cancer
Intervention
- Drug: IMGN151
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
measured Up to approximately 3 years
Number of Participants With Dose-limiting Toxicities (DLTs)
measured Day 21 of Cycle 1 (Cycle length = 3 weeks)
Recommended Dose of IMGN151 Monotherapy
measured Up to approximately 2 years
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed